Anil Parwani, MD, PhD, discusses the challenges and opportunities he has encountered in either implementing or utilizing ...

During a Case-Based Roundtable® event, Samer A. Al'Hadidi, MD, MS, discussed the CARTITUDE-4 trial of cilta-cel in patients ...

Hamlet Gasoyan, MD, discusses what to know from a study that found there to be disparities in time to treatment with oral antimyeloma medications when used in patients with newly diagnosed multiple ...

The decision to discontinue BTK inhibitor treatment for CLL is complex, with emerging data suggesting that time-limited ...

The approval is supported by data from the phase 3 IMROZ study which demonstrated superior progression-free survival with ...

BAY 2927088, an oral, reversible tyrosine kinase inhibitor (TKI) that potently inhibits mutant HER2, led to promising response rates when used for the treatment of patients with pretreated HER2 ...

In an interview with Targeted Oncology, Mark R. Litzow, MD, discussed the incorporation of Immunotherapy into upfront acute ...

Jacob E. Berchuck, MD, discusses research behind using a blood-based liquid biopsy over traditional PSMA PET scans presented ...

During a Case-Based Roundtable® event, Ajay Nooka, MD, MPH, discussed adverse events related to talquetamab for multiple ...